Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 15/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6423157 | 0.85 | GAA (0.57) | GAAKMT2ATDP1MEN1SMN1; SMN2 | |
| SCHEMBL2203244 | 0.82 | GAA (0.64) | GAAKMT2ATDP1MEN1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL28865546 | 0.81 | GAA (0.62) | GAAKMT2ATDP1MEN1SMN1; SMN2 | |
| SCHEMBL6424637 | 0.78 | GAA (0.49) | GAAKMT2ATDP1MEN1SMN1; SMN2 | |
| SCHEMBL5843055 | 0.75 | GRIN2B (0.58) | GAAALDH1A1SMYD3 | |
| SCHEMBL7564279 | 0.74 | GRIN2B (0.57) | GAAALDH1A1SMYD3 | |
| SCHEMBL5841131 | 0.73 | GAA (0.97) | GAAKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL4046212 | 0.73 | GAA (0.57) | GAATDP1SMN1; SMN2SMYD3 | |
| Dimethylformamide SCHEMBL27577776 | 0.73 | GAA (0.53) | GAAKMT2ATDP1MEN1SMN1; SMN2 | |
| SCHEMBL12431407 | 0.72 | GAA (1.00) | GAAKMT2AMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1427326-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | SUGEN INC (US) | 2005-06-08 | — | — | EP | disclosed |
| EP-1427326-A2 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | Sugen, Inc. (US) | 2004-06-16 | — | — | EP | disclosed |
| WO-2003015608-A2 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | SUGEN, INC. (US) | 2003-02-27 | — | — | WO | disclosed |
| EP-1255752-A2 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | Sugen, Inc. (US) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001060814-A2 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | SUGEN, INC. (US) | 2001-08-23 | — | — | WO | disclosed |